<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35481502</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1660-9379</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>779</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>27</Day></PubDate></JournalIssue><Title>Revue medicale suisse</Title><ISOAbbreviation>Rev Med Suisse</ISOAbbreviation></Journal><ArticleTitle>[Cramps and fasciculations: is it amyotrophic lateral sclerosis?].</ArticleTitle><Pagination><StartPage>790</StartPage><EndPage>793</EndPage><MedlinePgn>790-793</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53738/REVMED.2022.18.779.790</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease of the adult age. It is an aggressive condition with a mean disease duration of only 3 to 5 years, characterized by progressive weakness and atrophy of limb, bulbar, and respiratory muscles. In general, death is caused by chronic hypoventilation due to respiratory insufficiency. No causal treatment is known today, but the two therapeutic agents authorized in Switzerland for the treatment of ALS can slow disease progression significantly. Other important therapeutic strategies include invasive/non-invasive ventilation, pain therapy, as well as physio-, ergo- and speech therapy on a regular basis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H&#xfc;bers</LastName><ForeName>Annemarie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de neurologie, D&#xe9;partement des neurosciences cliniques, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fayolle</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service de neurologie, D&#xe9;partement des neurosciences cliniques, H&#xf4;pitaux universitaires de Gen&#xe8;ve, 1211 Gen&#xe8;ve 14.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ochsner</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Service de neurologie, D&#xe9;partement des neurosciences cliniques, Centre hospitalier universitaire vaudois et Universit&#xe9; de Lausanne, 1011 Lausanne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Echaniz-Laguna</LastName><ForeName>Andoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de neurologie, Centre de r&#xe9;f&#xe9;rence national pour les neuropathies rares, CHU de Bic&#xea;tre, 78 rue du G&#xe9;n&#xe9;ral-Leclerc, 94270 Le Kremlin-Bic&#xea;tre, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universit&#xe9; Paris-Saclay, 3 rue Joliot-Curie, 91190 Gif-sur-Yvette, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magy</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service et laboratoire de neurologie, Centre de r&#xe9;f&#xe9;rence neuropathies p&#xe9;riph&#xe9;riques rares, CHU de Limoges, 2 avenue Martin-Luther-King, 87042 Limoge, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vicino</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de neurologie, D&#xe9;partement des neurosciences cliniques, Centre hospitalier universitaire vaudois et Universit&#xe9; de Lausanne, 1011 Lausanne.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Th&#xe9;audin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Service de neurologie, D&#xe9;partement des neurosciences cliniques, Centre hospitalier universitaire vaudois et Universit&#xe9; de Lausanne, 1011 Lausanne.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Crampes et fasciculations&#x2009;: est-ce une scl&#xe9;rose lat&#xe9;rale amyotrophique&#x2009;?</VernacularTitle></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Rev Med Suisse</MedlineTA><NlmUniqueID>101219148</NlmUniqueID><ISSNLinking>1660-9379</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005207" MajorTopicYN="N">Fasciculation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009120" MajorTopicYN="N">Muscle Cramp</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N" Type="Geographic">Switzerland</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="fre"><AbstractText>La scl&#xe9;rose lat&#xe9;rale amyotrophique (SLA) est la maladie du motoneurone la plus fr&#xe9;quente de l&#x2019;adulte. C&#x2019;est une maladie s&#xe9;v&#xe8;re (la survie moyenne est d&#x2019;environ 3 &#xe0; 5 ans), caract&#xe9;ris&#xe9;e par une d&#xe9;g&#xe9;n&#xe9;rescence des premier et deuxi&#xe8;me motoneurones. Elle se manifeste par un d&#xe9;ficit moteur amyotrophiant progressif des membres, de la langue, des muscles bulbaires et respiratoires. En g&#xe9;n&#xe9;ral, le d&#xe9;c&#xe8;s est caus&#xe9; par une hypoventilation chronique. Il n&#x2019;existe actuellement aucun traitement curatif. Les deux m&#xe9;dicaments autoris&#xe9;s en Suisse peuvent ralentir significativement la progression de la maladie et plusieurs nouvelles mol&#xe9;cules sont &#xe0; l&#x2019;essai. Les traitements non m&#xe9;dicamenteux/symptomatiques constituent le deuxi&#xe8;me pilier de la prise en charge&#x2009;: ventilation non invasive, traitement des sympt&#xf4;mes bulbaires, stabilisation du poids, physio et ergoth&#xe9;rapie.</AbstractText></OtherAbstract><CoiStatement>Les auteurs n&#x2019;ont d&#xe9;clar&#xe9; aucun conflit d&#x2019;int&#xe9;r&#xea;ts en relation avec cet article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>8</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35481502</ArticleId><ArticleId IdType="doi">10.53738/REVMED.2022.18.779.790</ArticleId><ArticleId IdType="pii">RMS0779-003</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>